Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global $28.8 Billion Pain Therapeutics Market, 2023

This image opens in the lightbox

News provided by

Research and Markets

10 Jul, 2017, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, July 10, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse" report to their offering.

Pain therapeutics market is forecast to grow from US$19.7 Billion in 2016 to US$28.8 Billion in 2023 at a compound annual growth rate (CAGR) of 5.5%.

"Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse" provides an introduction to the pain market, including disease epidemiology, symptoms, diagnosis, pathophysiology and co-morbidities and complications.

The US market alone is forecast to be worth US$13.5 Billion in 2023, accounting for 45.2% of the overall pain therapeutics market. Generic products are the main source of market revenue, accounting for over 50% of total market revenue in 2016. This is due mainly to the widespread usage (particularly in the US) of generic opioids, which are far more expensive than other generic analgesics.

There are 817 products in the pain therapeutics pipeline, including 75 for migraine, 118 for inflammatory pain and 255 for neuropathic pain. Some 63% of the pipeline is in the early drug development stages. The most promising drugs within the pipeline include those drugs belonging to the new class of migraine medication, the CGRPR antagonists that have been shown to be an effective preventative therapy for migraines. This class of drugs is forecast to generate an aggregate of US$5 Billion revenue by 2023.

A total of 363 licensing deals for pain therapeutics were completed between 2006 and April 2017, with an aggregate disclosed value of US$11.8 Billion. This highlights pharmaceutical company's interest in investment in analgesics. These deals varied considerably in terms of value, ranging from US$20,000 to US$1.5 Billion. Over 40 deals were valued at less than US$10m, while 19 were valued above US$200m.

Key Topics Covered:

1 Introduction

1.1 Disease Cluster Introduction

1.2 Symptoms

1.2.1 Migraine

1.2.2 Inflammatory pain and neuropathic pain

1.3 Diagnosis

1.4 Pathophysiology

1.4.1 Nociceptive pain transmission

1.4.2 Pain modulation in the brain

1.4.3 Inflammatory pain

1.4.4 Migraine

1.4.5 Neuropathic pain

1.5 Epidemiology

1.5.1 Migraine

1.5.2 Inflammatory pain

1.5.3 Neuropathic pain

1.6 Comorbidities and Complications

1.7 Treatment

1.7.1 Non-steroidal anti-inflammatory drugs

1.7.2 Opioid medications

1.7.3 Triptans

1.7.4 Other medications

1.7.5 Conclusion

2 Key Marketed Products

2.1 Celebrex (celecoxib) - Pfizer

2.2 Nucynta (tapentadol) - Depomed

2.3 Lyrica (pregabalin) - Pfizer

2.4 Exparel (bupivacaine) - Pacira

2.5 Voltaren (diclofenac sodium) - Novartis

2.6 Pennsaid (diclofenac sodium) - Horizon

2.7 Depakine (valproate sodium) - Daiichi Sankyo

2.8 Embeda ER (morphine sulfate + naltrexone) - Pfizer

2.9 Cymbalta (duloxetine hydrochloride) - Eli Lilly

2.10 Conclusion

3 Pipeline Landscape Assessment

3.1 Overview

3.2 Pipeline Development Landscape

3.3 Molecular Targets in the Pipeline

3.4 Clinical Trial Landscape

3.4.1 Failure Rate by Stage of Development, Indication and Molecule Type

3.4.2 Clinical Trial Duration by Stage of Development, Indication, and Molecule Type

3.4.3 Clinical Trial Size by Stage of Development, Indication and Molecule Type

3.4.4 Aggregate Clinical Program Size by Stage of Development, Indication and Molecule Type

3.5 Conclusion

3.6 Assessment of Key Pipeline Products

3.6.1 HTX-011 - Heron

3.6.2 Difelikefalin - Cara

3.6.3 Fremanezumab - Teva

3.6.4 Eptinezumab - Alder

3.6.5 Erenumab - Amgen and Novartis

3.6.6 Galcanezumab - Eli Lilly

3.6.7 Zilretta - Flexion

3.6.8 EMA-401 - Novartis

3.6.9 Conclusion

4 Multi-scenario Market Forecast to 2022

4.1 Overall Market Size

4.2 Generic Penetration

4.2.1 Generic Opioid Usage

4.3 Revenue Forecast by Molecular Target

4.3.1 Opioid Receptors

4.3.2 Serotonin Receptors 1B and 1D

4.3.3 Prostaglandin G/H Synthase (COX)

4.3.4 Calcitonin Gene Related Peptide Receptors

4.3.5 Multiple Targets

4.3.6 Ion Channels

5 Company Analysis and Positioning

5.1 Revenue and Market Share Analysis by Company

5.1.1 Teva - Company Set to Enter the Market and Secure Large Market Share by 2023

5.1.2 Pfizer - Key Patent Expiries to Drive Negative Growth

5.1.3 Pacira - Company to Secure a Large Market Share despite Small Product Portfolio

5.1.4 Novartis - Expansion of Pain Therapeutics Portfolio for the First Time since Voltaren

5.1.5 Amgen - Company Set to Enter Pain Market in Early Forecast Period and Achieve Rapid Growth

5.1.6 Allergan - Expansion of Product Portfolio to Drive Growth

5.1.7 Depomed - Revenue to Rise despite Upcoming Patent Cliff

5.1.8 Lilly - Lilly to Expand Position in Market as Patent for Cymbalta Expires

5.2 Company Landscape

5.3 Marketed and Pipeline Portfolio Analysis

6 Strategic Consolidations

6.1 Licensing Deals

6.1.1 Deals by Region, Value and Year

6.1.2 Deals by Indication

6.1.3 Deals by Stage of Development and Value

6.1.4 Deals by Molecule Type, Molecular Target and Value

6.1.5 Licensing Deals with Disclosed Values

6.2 Co-development Deals

6.2.1 Deals by Region, Value and Year

6.2.2 Deals by Indication

6.2.3 Deals by Stage of Development and Value

6.2.4 Deals by Molecule Type and Value

6.2.5 Co-development Deal with Disclosed Values

7 Appendix

For more information about this report visit

https://www.researchandmarkets.com/research/zx9g6m/global_pain

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.